{
    "name": "interferon gamma 1b",
    "comment": "Rx",
    "other_names": [
        "Actimmune"
    ],
    "classes": [
        "Biological Response Modifiers"
    ],
    "source": "https://reference.medscape.com/drug/actimmune-interferon-gamma-1b-342202",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Not known whether excreted in breast milk, discontinue drug or do not nurse"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known whether excreted in breast milk, discontinue drug or do not nurse"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to interferon gamma or E. coli-derived products"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Immunocompromised patients",
                "Potential for hepatotoxicity",
                "If severe reactions occur, decrease dose 50% or withhold until side effects subside",
                "Caution in cardiovascular disease; pre-existing cardiac conditions may be exacerbated",
                "Reduce dose or discontinue if decreased mental status, gait disturbance, dizziness occur",
                "Monitor for neutropenia and thrombocytopenia particularly when administering in combination with other potentially myelosuppressive agents",
                "Reduce dose or discontinue to reverse severe elevations of aspartate transaminase (AST) and/or alanine transaminase (ALT); monitor liver function monthly in patients <1 year old",
                "If serious hypersensitivity reactions occur, discontinue and institute appropriate medical therapy",
                "Monitor renal function regularly when administering therapy to patients with severe renal insufficiency",
                "Refrigerate vials-do not freeze or shake",
                "The stopper of the glass vial contains natural rubber (a derivative of latex) which may cause allergic reactions",
                "May cause flu-like symptoms",
                "No preservatives-discard unused portions"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, interferon gamma 1b.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, interferon gamma 1b.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, interferon gamma 1b.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and interferon gamma 1b both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "interferon gamma 1b, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Cutaneous vasculitic toxicities (eg, vasculitic ulcerations and gangrene) were reported during therapy with hydroxyurea in patients with a history of, or currently receiving, interferon therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, interferon gamma 1b.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and interferon gamma 1b both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and interferon gamma 1b both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "interferon gamma 1b increases levels of theophylline by decreasing metabolism. Use Caution/Monitor. Greater risk of interaction in smokers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and interferon gamma 1b both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fever",
            "percent": "52"
        },
        {
            "name": "Headache",
            "percent": "33"
        },
        {
            "name": "Rash",
            "percent": "17"
        },
        {
            "name": "Chills",
            "percent": "14"
        },
        {
            "name": "Diarrhea",
            "percent": "14"
        },
        {
            "name": "Injection site erythema",
            "percent": "14"
        },
        {
            "name": "tenderness",
            "percent": "13"
        },
        {
            "name": "Vomiting",
            "percent": "10"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        }
    ]
}